Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft synthesis: Bacterial endotoxin in research-supply… — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-116/3
Series
Public comment period
Version
1.0
Published
10 Aug 2026
Last reviewed
10 Aug 2026
Next review
10 Aug 2027
Identifier
10.71829/cei.cp.116
Certainty
Not rated
Cycle
2026 Q3
Window
10 Aug 2026 – 05 Oct 2026
Status
Open
Submissions
2

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-ENDOTOXIN-IN/001Dr Hamish Nyquist-ObioraIntention-to-treat and efficacy-estimand results are combined without distinctionAccepted
DRAFT-ENDOTOXIN-IN/002Dr Katarzyna Oppenheimer-AdeRisk-of-bias judgements are reported as an overall rating without the domainsAccepted
2 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted2The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part0Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment0The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted0The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. Intention-to-treat and efficacy-estimand results are combined without distinction — arising from DRAFT-ENDOTOXIN-IN/001. The treatment-policy estimand is used throughout as the primary analysis, the efficacy estimand is reported as a secondary analysis where available, and the estimand used is stated in every row of the summary of findings.
  2. Risk-of-bias judgements are reported as an overall rating without the domains — arising from DRAFT-ENDOTOXIN-IN/002. Risk of bias is now reported at domain level for every included study, with the text on which each judgement was based quoted and referenced, and the overall judgement derived from the domains rather than asserted alongside them.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.